

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Autoimmune disease</b>				
Multiple sclerosis (MS)	Tumor necrosis factor receptor superfamily member 21 (TNFRSF21; DR6)	<i>In vitro</i> and rodent studies suggest antagonizing DR6 could help treat MS. In coculture of oligodendrocyte precursor cells and dorsal root ganglion neurons, small interfering RNA or an antibody against DR6 increased myelination compared with siRNA or antibody controls. In rat models of experimental autoimmune encephalomyelitis (EAE) and lipopolysaccharide (LPS)-induced demyelination, the anti-DR6 antibody induced remyelination, whereas the control antibody did not. Next steps include identifying a lead therapeutic candidate.	Patent application filed by Biogen Idec Inc.; unavailable for licensing	Mi, S. <i>et al. Nat. Med.</i> ; published online July 3, 2011; doi:10.1038/nm.2373 <b>Contact:</b> Sha Mi, Biogen Idec Inc., Cambridge, Mass. e-mail: <a href="mailto:sha.mi@biogenidec.com">sha.mi@biogenidec.com</a>
<p><i>SciBX</i> 4(28); doi:10.1038/scibx.2011.787 Published online July 21, 2011</p>				